文献速递白血病

成人急性淋巴细胞白血病患者接受儿童方案一线治疗后中枢神经系统复发的发生率、治疗与结局:Campus ALL多中心回顾性研究

Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study.
PubMed 文献 · Br J Haematol · 2022-11-06

在Campus ALL协作网内,分析了2009至2020年间1035例接受儿童方案一线治疗的成人急性淋巴细胞白血病(ALL)患者中枢神经系统(CNS)复发的发生率、特征、治疗与结局。71例(6.8%)发生CNS复发,T-ALL较B-ALL更常见(10% vs 5.7%,p=0.017)。早期CNS复发(诊断后<12个月)41例,多因素分析危险因素包括T细胞表型、高白细胞>100×10^9/L和男性。治疗后39例(55%)获完全缓解,缓解后26例接受异基因移植,较未移植者总生存显著获益(p=0.012)。中位观察8个月,23例(32%)存活;多因素分析中CNS复发时间是复发后2年生存率降低的最强预测因素(p<0.001)。结论:成人ALL发生CNS复发后结局仍很差,有效的CNS预防仍是最佳策略,应尽可能进行异基因移植。

要点

  • 1035例成人ALL中71例(6.8%)发生CNS复发,T-ALL 10%高于B-ALL 5.7%(p=0.017)。
  • 早期CNS复发(<12个月)41例,危险因素为T细胞表型、高白细胞>100×10^9/L和男性。
  • CNS复发后39例(55%)获完全缓解,缓解后26例接受异基因移植者总生存显著获益(p=0.012)。

核心结论

  • 成人ALL发生CNS复发后结局仍很差,有效的CNS预防仍是最佳策略,应尽可能进行异基因移植。

研究设计与样本

  • Campus ALL协作网多中心回顾性研究,纳入2009至2020年间1035例接受儿童方案一线治疗的成人ALL患者。

主要发现

  • 71例(6.8%)发生CNS复发,T-ALL 28/278(10%)高于B-ALL 43/757(5.7%)(p=0.017)。
  • 早期CNS复发(诊断后<12个月)41例,多因素分析危险因素包括T细胞表型(p<0.001)、高白细胞>100×10^9/L(p<0.001)和男性(p=0.015)。
  • CNS复发后39例(55%)获完全缓解,不同治疗策略间无差异。
  • 完全缓解后26例接受异基因移植,较未移植患者总生存显著获益(p=0.012)。
  • 自CNS复发中位观察8个月,23例(32%)存活;多因素分析中CNS复发时间是复发后2年生存率降低的最强预测因素(p<0.001)。

临床怎么用

  • 作者认为有效的CNS预防仍是最佳策略,并建议尽可能进行异基因移植。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Within the Campus ALL network we analyzed the incidence, characteristics, treatment and outcome of a central nervous system (CNS) relapse in 1035 consecutive adult acute lymphoblastic leukemia (ALL) patients treated frontline with pediatric-inspired protocols between 2009 and 2020. Seventy-one patients (6.8%) experienced a CNS recurrence, more frequently in T- (28/278; 10%) than in B-ALL (43/757; 5.7%) (p = 0.017). An early CNS relapse-< 12 months from diagnosis-was observed in 41 patients. In multivariate analysis, risk factors for early CNS relapse included T-cell phenotype (p = <0.001), hyperleucocytosis >100 × 109 /L (p<0.001) and male gender (p = 0.015). Treatment was heterogeneous, including chemotherapy, radiotherapy, intrathecal therapy and novel agents. A complete remission (CR) was obtained in 39 patients (55%) with no differences among strategies. After CR, 26 patients underwent an allogenic transplant, with a significant overall survival benefit compared to non-transplanted patients (p = 0.012). After a median observation of 8 months from CNS relapse, 23 patients (32%) were alive. In multivariate analysis, the time to CNS relapse was the strongest predictor of a lower 2-year post-relapse survival (p<0.001). In conclusion, in adult ALL the outcome after a CNS relapse remains very poor. Effective CNS prophylaxis remains the best approach and allogenic transplant should be pursued when possible.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dargenio M, Bonifacio M, Chiaretti S, et al. Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study. Br J Haematol. 2022. PMID: 36335916. doi:10.1111/bjh.18537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。